Abstract:Synthesis of new bioactive heterocyclic compounds bearing phosphorus and silicon moieties. The reaction of phosphacumulene and phosphallene ylides with iso(thio)cyanates resulted in the formation of different four‐, and six‐membered heterocyclic compounds containing one phosphorus or two phosphorus atoms. Molecular docking studies are carried out for the most active compounds 11 and 15 which are considered as potential MMP‐2 inhibitors. Matrix metalloproteinases (MMPs) attracted medicinal chemists as they are biological targets that are involved in various pathophysiological processes such as extracellular matrix protein degradation, cell‐surface receptor release and cleavage, tumor growth, homeostatic control, and innate immunity. New heterocycles, bearing both silicon and phosphorus in their molecular structures, were successfully produced via reacting silylated isocyanates and/or isothiocyanates with appropriate phosphorus ylides. Reacting nucleophilic phosphacumulenes (2,6) with isocyanate 1 and isothiocyanate 9 yielded four‐membered ring heterocycles containing phosphorus and silicon (4 and 11) and six‐membered rings heterocycles (5, 8 and 12). Moreover, novel heterocycles containing two phosphorus atoms and one silicon atom were produced by the reaction of diphosphorane 13 with 1 or 9. On the other side, four‐membered (23, 26 and 29a) and six‐membered heterocyclic derivatives (20b and 29b) containing two phosphorus atoms in their structures were also obtained from the reaction of phosphallene ylide 13 and substrates (18, 21, 24 and 27). All the final compounds were tested for their MMP‐2 inhibitor activity showing IC50 values in the range of 0.0408–0.4985 μM. The thiolactam derivative 11 and the azaphosphetidin‐4‐one derivative 15, both bearing silicon and phosphorous, showed the highest activity with IC50 values of 0.0408 and 0.0693 μM, respectively, both are significantly higher than that of quercetin (IC50 = 0.1631 μM). Docking simulations were carried out for the most two active compounds 11 and 15 in the vicinity of the active site of MMP‐2 enzyme and both formed coordinate bonds with the zinc cation key interaction for MMP‐2 enzyme. In conclusion, compounds 11 and 15 can be considered as potential MMP‐2 inhibitors and can be subjected to further studies as antimetastatic agents.

Sulfonamide Derivatives Containing Dihydropyrazole Moieties Selectively and Potently Inhibit Mmp-2/Mmp-9: Design, Synthesis, Inhibitory Activity and 3D-Qsar Analysis

Design, Synthesis, Evaluation and 3D-QSAR Analysis of Benzosulfonamide Benzenesulfonates As Potent and Selective Inhibitors of MMP-2

Synthesis, Biological Evaluation, and Docking of Dihydropyrazole Sulfonamide Containing 2‐hydroxyphenyl Moiety: A Series of Novel MMP‐2 Inhibitors

QSAR Studies of Sulfonamide Hydroxamates Derivatives as MMP-2 Inhibitors Topomer CoMFA and Molecular Docking

Dihydropyrazothiazole Derivatives As Potential MMP-2/MMP-8 Inhibitors for Cancer Therapy.

Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation

Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.

Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Sulfonamides containing coumarin moieties selectively and potently inhibit carbonic anhydrases II and IX: design, synthesis, inhibitory activity and 3D-QSAR analysis.

Design, Synthesis, Antitumor Activity Evaluation, and Molecular Dynamics Simulation of Some 2-Aminopyrazine Derivatives

Pinpointing prime structural attributes of potential MMP-2 inhibitors comprising alkyl/arylsulfonyl pyrrolidine scaffold: a ligand-based molecular modelling approach validated by molecular dynamics simulation analysis

Design, Synthesis and Biological Evaluation of Pyridine Acyl Sulfonamide Derivatives As Novel COX-2 Inhibitors

Discovery of Highly Potent and Selective Matrix Metalloproteinase-7 Inhibitors by Hybridizing the S1' Subsite Binder with Short Peptides

Synthesis, biological evaluation and molecular modeling of dihydro-pyrazolyl-thiazolinone derivatives as potential COX-2 inhibitors.

Exploration of structural alerts and fingerprints for novel anticancer therapeutics: a robust classification-QSAR dependent structural analysis of drug-like MMP-9 inhibitors

Synthesis and Antitumor Activity of 1,3,4-Oxadiazole Possessing 1,4-Benzodioxan Moiety As a Novel Class of Potent Methionine Aminopeptidase Type II Inhibitors

Design, synthesis, and biological evaluation of new heterocycles bearing both silicon and phosphorus as potent MMP‐2 inhibitors

Biphenylsulfonamides as effective MMP-2 inhibitors with promising antileukemic efficacy: Synthesis, in vitro biological evaluation, molecular docking, and MD simulation analysis

Design of novel potent selective survivin inhibitors using 2D-QSAR modeling, molecular docking, molecular dynamics, and ADMET properties of new MX-106 hydroxyquinoline scaffold derivatives